Quintiles has launched a local contract research organization (CRO), Kun Tuo in China to cater to the needs of Chinese biopharmaceutical industry.
Subscribe to our email newsletter
Kun Tuo will lay emphasis on the development of customized solutions to help local and global biopharma companies achieve registration of new medicines in China.
In addition the CRO will also provide a portfolio of services, including comprehensive clinical trial management, regulatory submission preparation, biostatistics and data management.
Kun Tuo is believed to make use of Quintiles’ global resources and expertise to develop customized offerings in key therapeutic areas, besides vaccines, late phase studies, medical devices and diagnostics.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.